Who is sponsoring NCT06369519?

NCT06369519 is sponsored by Peking University First Hospital.

What drugs are being tested in NCT06369519?

Interventions in NCT06369519: Surgery treatment or local tumor destruction..

What condition does NCT06369519 study?

NCT06369519 studies Kidney Cancer.

Is NCT06369519 still recruiting?

NCT06369519 is currently completed. Last updated 17 April 2024.

Last reviewed 2024-04-17 · How we verify

NCT06369519

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimization of Management for Sporadic Bilateral Renal Cell Carcinoma

Completed Last updated 17 April 2024

What this trial tests

trial testing Surgery treatment or local tumor destruction. in Kidney Cancer in 3,677 participants. Completed in 31 December 2020.

Timeline

1 January 2000

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Peking University First Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3,677
Start date	1 January 2000
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across China

Drugs / interventions tested

Surgery treatment or local tumor destruction.

Conditions studied

Kidney Cancer — all drugs for Kidney Cancer →

Sponsor

Peking University First Hospital

Who can join

18 and older, any sex, with Kidney Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sporadic bilateral renal cell carcinoma (BRCC) is a rare situation of RCC. The treatment for BRCC is controversial and there is a lack of authoritative guidelines about the management of BRCC. The goal of this cohort study is to identify prognostic factors, construct predictive nomograms, and optimize management for sporadic BRCC patients. The main questions it aims to answer are: What are the factors influencing the prognosis of BRCC patients? What's the appropriate treatment for BRCC patients? Researchers will analysis the prognostic factors and compare the prognosis of BRCC patients receiving different treatments.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The long-term survival outcome of sporadic bilateral renal cell carcinoma and optimization of surgical treatment: a large-scale population-based cohort study.
Deng R, Qiu J, Shang J, Yu C, et al · · 2024 · cited 3× · PMID 39708253 · DOI 10.1007/s10238-024-01535-5

Verify or expand the search:

Other recruiting trials for Kidney Cancer

Currently open trials in the same condition.

NCT07401875 — A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) · Phase 1 · recruiting
NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
NCT06964958 — 177LuPSMA in Renal Cell Carcinoma · Phase 2 · active not recruiting

Other Peking University First Hospital trials

Trials by the same sponsor.

NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06369519 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
Last refreshed: 17 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06369519.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing